A Multicenter, Double-blind, Randomized, Placebo-controlled Trial of the β3-Adrenoceptor Agonist Solabegron for Overactive Bladder

Abstract Background β-Adrenoceptor agonists are effective in animal models of bladder dysfunction, and the human bladder primarily expresses the β3 receptor subtype. Objective To evaluate the efficacy and tolerability of the highly selective and potent β3-adrenoceptor agonist solabegron in a clinica...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European urology 2012-11, Vol.62 (5), p.834-840
Hauptverfasser:	Ohlstein, Eliot H, von Keitz, Alexander, Michel, Martin C
Format:	Artikel
Sprache:	eng
Schlagworte:	Adrenergic beta-3 Receptor Agonists - administration & dosage Adrenergic beta-3 Receptor Agonists - adverse effects Adrenergic beta-3 Receptor Agonists - therapeutic use Adult Aged Aniline Compounds - administration & dosage Aniline Compounds - adverse effects Aniline Compounds - therapeutic use Argentina Australia Benzoates - administration & dosage Benzoates - adverse effects Benzoates - therapeutic use Biological and medical sciences Biphenyl Compounds - administration & dosage Biphenyl Compounds - adverse effects Biphenyl Compounds - therapeutic use Double-Blind Method Drug Administration Schedule Europe Female Humans Linear Models Medical sciences Middle Aged Nephrology. Urinary tract diseases New Zealand Overactive bladder Republic of Korea Solabegron South Africa Taiwan Time Factors Treatment Outcome Urinary Bladder - drug effects Urinary Bladder - physiopathology Urinary Bladder, Overactive - drug therapy Urinary Bladder, Overactive - physiopathology Urinary incontinence Urinary Incontinence - drug therapy Urinary Incontinence - physiopathology Urinary system involvement in other diseases. Miscellaneous Urinary tract. Prostate gland Urination - drug effects Urodynamics - drug effects Urology Young Adult β3-adrenoceptor
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!